Contract research services provider, GVK Biosciences today said it has entered into a strategic partnership with US-based Quantitative Solutions (QS) to develop and market clinical trial outcome data base.
As per the terms of the agreement, GVK Bio will distribute Quantitative Solutions' existing data base in five therapeutic areas, GVK Biosciences said in a statement.
The Indian firm would market the existing data base of the American company in therapeutic areas such as rheumatoid arthritis & psoriasis, chronic HCV, neuropathic pain, osteoporosis and major depressions, it added.
Besides this, GVK and QS plan to jointly develop and market additional databases in dyslipodemia, schizophrenia, alzheimer's and in other areas shortly, the company said.
"We have seen significant increase in demand for this type of analysis and are excited about the opportunity to work with GVK Bio to expand product offerings in clinical outcome databases," QS Founder and CEO Jaap Mandema said.
QS is a leading scientific consultancy to the pharmaceutical and biotech industry.
